|« Previous month||Next month »|
28-Feb-2017 - Fujifilm has separated its biopharmaceutical contracting business in an effort to triple its revenues to ¥100bn ($890m) within seven years.
28-Feb-2017 - Aska Pharmaceutical Co. Ltd has bought an option to commercialize Pieris Pharmaceuticals’ anaemia candidate and EPO rival, PRS-080, in Japan.
28-Feb-2017 - A Californian manufacturing facility to support clinical development of a haemophilia A gene therapy will be completed this year, says BioMarin.
27-Feb-2017 - Sanofi and Lonza will construct a large-scale mammalian cell culture manufacturing site in Switzerland, with an initial investment of CHF 290m ($288m).
24-Feb-2017 - TxCell has raised €11m ($11.6m) through a share issue which it will use to fund first-in-man study of one of its cell therapy candidates.
24-Feb-2017 - LegoChem Biosciences has teamed up with Novimmune to develop and test antibody drug conjugate (ADC) drug.
23-Feb-2017 - Ohr Pharmaceutical Inc. has halted activities at the laboratory in San Diego, California where research on its sustained release delivery technology was carried out.
22-Feb-2017 - The European Commission has approved Celltrion Healthcare’s rituximab biosimilar – Truxima (CT-P10) – for the same autoimmune disease and cancer indications as the reference product.
22-Feb-2017 - Celyad SA has enrolled the first multiple myeloma patient in a safety and tolerability trial of its CAR-T therapy.
22-Feb-2017 - Vaccines do not cause autism and people who say otherwise are wrong.
21-Feb-2017 - Cambridge Research Biochemicals (CRB) has launched a second catalogue of research antibodies for academia, pharma and outsourcing firms.
21-Feb-2017 - Sanofi has contracted Swiss biotech Selexis SA to develop cell lines for a three early stage projects.
21-Feb-2017 - Abzena Plc has been contracted to make an antibody drug candidate for wet age-related macular degeneration by developers at University College London.
21-Feb-2017 - CellGenix GmbH has started expanding its cell and gene therapy reagents facility in Freiburg, Germany citing the progression of customer projects into clinical development and commercial launch.
20-Feb-2017 - The Research Institute for Chromatography (RIC) and Anacura have joined forces to create anaRIC biologics, an R&D and GMP analytical specialist CRO for biologics.
17-Feb-2017 - Selecta Biosciences Inc. has hired Swiss contractor Lonza to make a gene therapy candidate for the metabolic disease, Methylmalonic Acidemia (MMA).
17-Feb-2017 - TiGenix is using Lonza as a US CMO and Takeda as an ex-US commercialization partner to launch and trial its off-the-shelf stem cell therapy for a complication of Crohn’s disease....
17-Feb-2017 - Charles River Laboratories says it is positioning itself to take advantage of growing demand for biological services.
17-Feb-2017 - Contract research organisation (CRO) ICON has taken a hit to its book-to-bill ratio after Pfizer dropped its anti-cholesterol candidate bococizumab in November.
17-Feb-2017 - Biocon’s biomanufacturing facilities in India will need a “meaningful capacity expansion” to cope with long-term global biosimilar demand, the firm says.
15-Feb-2017 - CMOs will struggle to compete with large in-house capacity investments, according to Results Healthcare which predicts a decline in outsourced biomanufacturing.
15-Feb-2017 - Industry group the Biosimilars Forum has welcomed President Trump’s pick of Representative Tom Price as Secretary of Health and Human Services.
14-Feb-2017 - Orgenesis’ Belgian subsidiary, Orgenesis SPRL, has received €12.3m ($12.8m) to further develop its Type 1 Diabetes program.
14-Feb-2017 - Thermo Fisher Scientific says it is buying Finesse Solutions, its long-term supplier of measurement and control solutions for bioprocessing applications.
14-Feb-2017 - Rumours of an Irish expansion freeze have been greatly exaggerated according to Eli Lilly, which says it remains committed to its Kinsale biomanufacturing site.
|« Previous month||Next month »|